Stelara And Firmagon Suffer Setbacks In Draft NICE Appraisals
This article was originally published in The Pink Sheet Daily
Executive Summary
Janssen has until Jan. 17 to argue the cost-effectiveness of Stelara in the additional indication, psoriatic arthritis, while Ferring faces a restricted indication recommendation for Firmagon.